Skip to main content

Table 1 Completed clinical trials targeting New York esophageal squamous cell carcinoma-1(NY-ESO-1) antigen

From: Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy

Immunotherapeutic strategy

Adjuvant/interventions

Indications

Phase

Trial ID

NY-ESO-1 protein vaccine

CpG 7909

Advanced prostate cancer

1

NCT00292045

Cholesteryl pullulan(CHP) + CHP HER2 + OK-432

Esophageal cancer, lung cancer, stomach cancer, breast cancer, ovarian cancer

1

NCT00291473

Glucopyranosyl lipid adjuvant stable emulsion (GLA-SE)

Melanoma, ovarian cancer, sarcoma non-small cell lung cancer, breast cancer

1

NCT02015416

Recombinant Fowl-Pox virus vector

Fallopian tube cancer, ovarian cancer, peritoneal cavity cancer

2

NCT00112957

Recombinant canarypox virus vector (ALVAC) 2 + TRIad of Co-stimulatory molecules B7-1, ICAM- and LFA-3.

Fallopian tube cancer, ovarian cancer, peritoneal cavity cancer

1

NCT00803569

ISCOMATRIX

Melanoma

2

NCT00518206

Imiquimod

Malignant melanoma

1

NCT00142454

NY-ESO-1 peptide vaccine

Montanide, montanide + carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly-ICLC)

Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer

1

NCT00616941

CpG 7909 + montanide ISA-51

Stage III/IV;resected Stage II, III, or IV non-small cell lung cancer or esophageal cancer

1

NCT00199836

None

Prostate cancer

1

NCT00616291

CpG 7909, CpG 7909 + montanide ISA 720

All NY-ESO-1 expressing tumors

1

NCT00819806

BCG vaccine, sargramostim

Bladder cancer

1

NCT00070070

Resiquimod

Melanoma

1

NCT00470379

NY-ESO-1 TCR

Palliative radiation therapy

Sarcoma

1

NCT02319824

NY-ESO-1 specific monoclonal antibody

Resiquimod and/or carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (poly-ICLC)

Advanced malignancies

1 and 2

NCT00948961